



All Registry communications to:
Automic
Group GPO
Box 5193
Sydney NSW 2001
Telephone (free call within Australia): 1300 288 664
ASX Code: IXC

16 January 2026

Upcoming Annual General Meeting of Shareholders

Dear Shareholder,

Invex Therapeutics Ltd ACN 632 145 334 (ASX: IXC or “the **Company**”), advises the 2025 Annual General Meeting will be held at Pathways Corporate, Level 3, 101 St Georges Terrace, Perth, WA 6000 on Tuesday, 17 February 2026 at 3.00pm (AWST) (**Meeting**).

Notice of Meeting

The Notice of Meeting and Explanatory Memorandum (**Notice**) for the Meeting is available online and can be viewed and downloaded by shareholders of the Company (**Shareholders**) from the Company’s website at invextherapeutics.com or the Company’s ASX market announcements platform at www.asx.com.au (ASX: IXC).

In accordance with sections 110C-110K of the Corporations Act 2001 (Cth) (as inserted by the Treasury Laws Amendment (2021 Measures No.1) Act 2021 (Cth)), shareholders will not be sent a hard copy of the Notice or Proxy Form unless Shareholders have already notified the Company that they wish to receive documents such as the Notice and Proxy Form in hard copy.

Voting by Proxy

Online

scan the QR code below using your smartphone



Lodge the Proxy Form online at <https://investor.automic.com.au/#/loginsah> by following the instructions:

Login to the Automic website using the holding details as shown on your holding statement.
Click on ‘View Meetings’ – ‘Vote’.

To use the online lodgment facility, Shareholders will need their holder number (Securityholder Reference Number (SRN) or Holder Identification Number (HIN)) as shown at the top of your holding statement.

For further information on the online proxy lodgment process, or if you require a hard copy Proxy Form, please contact the Company’s Share Registry, Automic Registry Services (**Automic**), at hello@automicgroup.com.au or via phone on 1300 288 664 (within Australia) or +61 2 9698 5414 (overseas).

Shareholder queries in relation to the Meeting

Shareholders can contact the Company Secretary with any questions prior to the meeting via email at admin@catalystcorporate.com.au

Copies of all Meeting related material including the Notice and the Company’s Annual Report, are available to download from the Company’s website and the Company’s ASX market announcements platform. In the event it is necessary or appropriate for the Company to make alternative arrangements for the Meeting, information will be provided to Shareholders via the ASX and the Company’s website.

Authorised for ASX release by the Joint Company Secretary.
Carla Healy



Notice of Annual General Meeting and Explanatory Memorandum

Invex Therapeutics Limited

ACN 632 145 334

Date: Tuesday 17 February 2026

Time: 3.00pm (WST)

Place: Pathways Corporate
Level 3, 101 St Georges Terrace
Perth WA 6000

For personal use only

IMPORTANT INFORMATION ABOUT THE MEETING

Entitlement to vote at the Annual General Meeting

A determination has been made by the Board under regulation 7.11.37 of the *Corporations Regulations 2001* that the persons eligible to vote at the Annual General Meeting are those who are registered Shareholders of the Company as at **3.00pm (WST)** on **Sunday 15 February 2026**, subject to any applicable voting exclusion.

Voting by proxy

- (a) A Shareholder entitled to attend and vote at the Annual General Meeting may appoint one proxy or, if the Shareholder is entitled to cast 2 or more votes at the Meeting, 2 proxies, to attend and vote instead of the Shareholder.
- (b) Where 2 proxies are appointed to attend and vote at the Meeting, each proxy may be appointed to represent a specified proportion or number of the Shareholder's voting rights at the Meeting.
- (c) A proxy need not be a Shareholder of the Company.
- (d) A proxy may be an individual or a body corporate. If a body corporate is appointed, the proxy form must indicate the full name of the body corporate and the full name or title of the individual representative of the body corporate for the Meeting.
- (e) A Proxy Form accompanies this Notice. If a Shareholder wishes to appoint more than 1 proxy, they may make a copy of the Proxy Form attached to this Notice. For the Proxy Form to be valid it must be received together with the power of attorney or other authority (if any) under which the form is signed, or a (notarially) certified copy of that power or authority by **3.00pm (WST)** on **Sunday 15 February 2026** at the share registry, being Automic, as follows:

Online	https://investor.automic.com.au/#/loginsah
By email	meetings@automicgroup.com.au
By post	Automic GPO Box 5193 Sydney NSW 2001
By facsimile	+ 61 2 8583 3040
In person	Automic Level 5, 126 Phillip Street Sydney NSW 2000

Shareholders and their proxies should be aware that:

- if proxy holders vote, they must cast all directed proxies as directed; and
- any directed proxies which are not voted will automatically default to the Chairman, who must vote the proxies as directed.

Proxy voting by the Chairman

Voting restrictions under the Corporations Act apply to certain Resolutions. Please refer to the "Voting Prohibitions" section below in the Explanatory Memorandum for further details in this regard.

However, the Chairman may vote an undirected proxy (i.e. a proxy that does not specify how it is to be voted), provided the Shareholder who has lodged the proxy has given an express voting direction to the Chairman to exercise the undirected proxy, even if the Resolution is connected with the remuneration of a member of Key Management Personnel.

The Chairman intends to vote all available undirected proxies in favour of each item of business.

If you complete a Proxy Form that authorises the Chairman to vote on your behalf as proxy, and you do not mark any of the boxes so as to give him directions about how your vote should be cast, then you will be taken to have expressly authorised the Chairman to exercise your proxy on Resolution 1.

In accordance with this express authority provided by you, the Chairman will vote in favour of Resolution 1. If you wish to appoint the Chairman as your proxy, and you wish to direct him how to vote, please tick the appropriate boxes on the Proxy Form.

If you appoint as your proxy any Director, except the Chairman, or any other Key Management Personnel or any of their Closely Related Parties and you do not direct your proxy how to vote on Resolution 1, he or she will not vote your proxy on that Resolution.

Shareholders intending to appoint the Chairman, a Director or any other member of Key Management Personnel or any of their Closely Related Parties as proxy are encouraged to direct them how to vote on all the Resolutions.

The Company will provide Shareholders the opportunity to ask questions during the Meeting in respect to the formal item of business as well as general questions in respect to the Company and its business at the conclusion of the Meeting.

All resolutions will be by poll

The Chairman intends to demand a poll on each of the Resolutions proposed at the Meeting. Each Resolution considered at the Meeting will therefore be conducted by a poll.

The Board considers voting by poll to be in the interests of Shareholders as a whole and is a way to ensure the views of as many Shareholders as possible are represented at the Meeting.

Questions from Shareholders

In order to provide an equal opportunity for all Shareholders to ask questions, we ask you to submit in writing any questions to the Company. Please send your questions via email to:

Company Secretary - admin@catalystcorporate.com.au

To assist the Board and the auditor in responding to any questions that you may have, written questions must be received by no later than **5.00pm (WST) on Friday 13 February 2026**

Your questions should relate to matters that are relevant to the business of the Annual General Meeting, as outlined in this Notice of Meeting and Explanatory Memorandum.

The Chairman will endeavour to address as many Shareholder questions and comments as possible during the course of the Meeting. However, there may not be sufficient time available at the meeting to address all of the questions and comments raised. Please note that individual responses may be sent to the enquiring party only, and may not be sent to all Shareholders.

Documents lodged with ASX

A copy of this Notice of Meeting and Explanatory Memorandum will be lodged with ASX. Neither ASX nor any of its officers take any responsibility for the contents of this document.

Important dates and times

Unless the Meeting is adjourned, important dates and times are as follows:

Last time/date for receipt of written questions	5.00 pm (WST) on Friday 13 February 2026
Last time/date for receipt of valid proxies	3.00 pm (WST) on Sunday 15 February 2026
Record time/date to determine Shareholders eligible to vote	3.00 pm (WST) on Sunday 15 February 2026
Meeting	3.00 pm (WST) on Tuesday 17 February 2026

For personal use only

NOTICE OF ANNUAL GENERAL MEETING

Notice is hereby given that an Annual General Meeting of Shareholders of Invex Therapeutics Ltd ACN 632 145 334 (**Company** or **Invex**) will be held on **Tuesday, 17 February 2026 at 3.00pm (WST)** at Pathways Corporate Level 3, 101 St Georges Terrace, Perth WA

BUSINESS OF THE MEETING

Shareholders are invited to consider the following items of business at the Annual General Meeting.

1. FINANCIAL STATEMENTS AND REPORTS

To receive and consider the annual financial report of the Company for the financial year ended 30 June 2025 together with the declaration of the Directors, the Director's report, the Remuneration Report and the auditor's report.

2. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT (NON-BINDING)

To consider and, if thought fit, to pass, with or without amendment, the following resolution as a **non-binding resolution**:

“That, for the purposes of section 250R(2) of the Corporations Act and for all other purposes, approval is given for the adoption of the Remuneration Report as contained in the Company's annual financial report for the financial year ended 30 June 2025.”

Note: the vote on this Resolution is advisory only and does not bind the Directors nor the Company.

3. RESOLUTION 2 – RE-ELECTION OF MR DAVID WHEELER AS DIRECTOR

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purpose of clause 15.2 of the Constitution, Listing Rule 14.4 and for all other purposes, Mr David Wheeler, a Director, retires by rotation, and being eligible, is re-elected as a Director as described in the Explanatory Memorandum.”

4. RESOLUTION 3 – ELECTION OF DIRECTOR – MR SIMON OWEN

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purpose of clause 15.4 of the Constitution, Listing Rule 14.4 and for all other purposes, Mr Simon Owen, a Director who was appointed to fill a casual vacancy on the 10 November 2025, retires and, being eligible, is elected as a Director as described in the Explanatory Memorandum.”

5. RESOLUTION 4 – ELECTION OF DIRECTOR – PROF WARREN HARDING AM

To consider and, if thought fit, to pass, with or without amendment, the following resolution as an **ordinary resolution**:

“That, for the purpose of clause 15.4 of the Constitution, Listing Rule 14.4 and for all other purposes, Prof Warren Harding AM, a Director who was appointed to fill a casual vacancy on the 10 November 2025, retires and, being eligible, is elected as a Director as described in the Explanatory Memorandum.”

6. RESOLUTION 5 – APPROVAL OF 7.1A MANDATE

To consider and, if thought fit, to pass, with or without amendment, the following resolution as a **special resolution**:

“That, for the purpose of Listing Rule 7.1A and for all other purposes, approval is given for the Company to issue up to that number of Equity Securities equal to 10% of the issued capital of the Company at the time of issue, calculated in accordance with the formula prescribed in Listing Rule 7.1A.2 and otherwise on the terms and conditions set out in Explanatory Memorandum.”

By order of the Board of Invex Therapeutics Ltd

Carla Healy and Tim Slate
Joint Company Secretaries

Friday 16 January 2026

For personal use only

EXPLANATORY MEMORANDUM

TO THE NOTICE OF 2025 ANNUAL GENERAL MEETING

This Explanatory Memorandum has been prepared to provide information which the Directors believe to be material to Shareholders in deciding whether or not to pass the Resolutions.

1. FINANCIAL STATEMENTS AND REPORTS

In accordance with the Corporations Act, the business of the Meeting will include receipt and consideration of the annual financial report of the Company for the financial year ended 30 June 2025 together with the declaration of the Directors, the Directors' report, the Remuneration Report and the auditor's report.

The Company will not provide a hard copy of the Company's annual financial report to Shareholders unless specifically requested to do so. The Company's annual financial report is available on its website at <https://invextherapeutics.com/>.

2. RESOLUTION 1 – ADOPTION OF REMUNERATION REPORT (NON-BINDING)

2.1 Background

Shareholders are asked to adopt the Company's Remuneration Report. The Remuneration Report is set out in the Company's 2025 Annual Report and is available from the Company's website (<https://invextherapeutics.com/>). The Remuneration Report:

- describes the policies behind, and the structure of, the remuneration arrangements of the Company and the link between the remuneration of executives and the Company's performance;
- sets out the remuneration arrangements in place for each Director and for certain members of the senior management team; and
- explains the differences between the basis for remunerating non-executive Directors and senior executives.

The vote on this item is advisory only and does not bind the Directors. However, the Board will take into account any discussion on this item and the outcome of the vote when considering the future remuneration policies and practices of the Company.

2.2 Voting Prohibition

The Company will disregard any votes cast on this resolution:

- (a) by or on behalf of a member of Key Management Personnel (**KMP**) named in the remuneration report for the year ended 30 June 2025, or that KMP's Closely Related Party, regardless of the capacity in which the vote is cast; and
- (b) as a proxy by a member of the KMP at the date of the meeting, or that KMP's Closely Related Party.

However, the Company will not disregard a vote if it is cast as a proxy for a person who is entitled to vote on this resolution:

- (c) in accordance with the directions of how to vote on the Proxy Form; or
- (d) by the Chairman pursuant to an express authorisation on the Proxy Form.

2.3 Board Recommendation

The Directors unanimously recommend that shareholders vote in favour of adopting the Remuneration Report.

2.4 Chairman's available proxies

The Chairman intends to vote all available proxies in favour of this Resolution.

3. RESOLUTION 2 – RE-ELECTION OF MR DAVID WHEELER AS DIRECTOR

3.1 Background

In accordance with Listing Rule 14.5, at every annual general meeting an election of Directors must take place. Listing Rule 14.4 prevents a Director from holding office (without re-election) past the third annual general meeting following the Director's appointment or 3 years, whichever is longer.

Clause 15.2 of the Constitution sets out the requirements for determining which Directors are to retire by rotation at an annual general meeting. Mr David Wheeler, who has held office since 8 November 2023 and being eligible, retires by rotation and seeks re-election. Further information about Mr David Wheeler is set out below.

Resolution 2 is an ordinary resolution for the re-election of Mr Wheeler as a Director. If the Resolution is not passed, Mr Wheeler will not be re-elected as a Director.

Mr David Wheeler

Position	Non-Executive Director
Biography	<p>Mr Wheeler has more than 30 years Executive Management, Directorship and Corporate Advisory experience. He is a foundation Director and Partner of Pathways Corporate a boutique Corporate Advisory firm that undertakes assignments on behalf of family offices, private clients and ASX listed companies.</p> <p>Mr Wheeler has successfully engaged in business projects in the USA, UK, Europe, New Zealand, China, Malaysia, Singapore and the Middle East. Mr Wheeler has been a Fellow of the Australian Institute of Company Directors and serves on public and private company boards currently holding a number of directorships and advisory positions in Australian ASX listed companies.</p>
Current Directorships	Cycliq Group Ltd, Protean Energy Ltd, Ragnar Metals Ltd, Avira Resources Ltd, MOAB Ltd, Earth Energy Ltd, OZZ Resources Ltd, Winchester Energy Ltd, PVW Resources Ltd and Yugo Metals Ltd
Former Directorships	Tyranna Resources Ltd – resigned July 2024 ColorTV Ltd – resigned September 2023 Wellfully Ltd – resigned June 2023 Health House International Ltd – May 2023
Relevant interest in Invox Shares	Nil

3.2 Board Recommendation

The Directors (other than Mr Wheeler) unanimously recommend that Shareholders vote in favour of Resolution 2.

3.3 Chairman's available proxies

The Chairman intends to vote all available proxies in favour of this Resolution.

4. RESOLUTION 3 – ELECTION OF DIRECTOR – MR SIMON OWEN

4.1 Background

The Company announced on 10 November 2025 that Simon Owen had been appointed as a non-executive Director effective immediately. Mr Owen offers himself up for election at this Meeting.

Resolution 3 is an ordinary resolution for the election of Mr Owen as a Director. If the Resolution is not passed, Mr Owen will not be elected as a Director.

4.2 Listing Rule and Constitutional Requirements

Under Listing Rule 14.4, a Director appointed to fill a casual vacancy or as an addition to the Board must not hold office, without re-election, past the next annual general meeting of the Company.

Clause 15.4 of the Constitution enables the Directors to appoint any person as a Director (either as a casual vacancy or an addition), provided that the relevant appointed director shall only hold office until the next annual general meeting and is eligible for re-election at that meeting.

As the Meeting is the Company's first annual general meeting since Mr Owen's appointment, in accordance with Listing Rule 14.4 and clause 15.4 of the Constitution, Mr Owen resigns as a Director at the Meeting and, being eligible, seeks approval to be elected as a Director pursuant to this Resolution.

Mr Simon Owen

Position	Non-Executive Director
-----------------	------------------------

Biography	Simon Owen has over 35 years of experience as a corporate and commercial lawyer and corporate advisor with a particular focus upon developing businesses, innovation and intellectual property and capital markets. He has acted as a chairman and director, both executive and non-executive, for a number of listed and unlisted public companies.
------------------	--

He also has considerable executive experience in the establishment and development of businesses in industries including information technology, biotech, health/medtech, pharmaceuticals, agriculture, blockchain and finance.

From 'start-up' through IPO and beyond, he has engaged not only as a legal and corporate advisor but as a founder, executive, mentor and director for businesses large and small, across a diverse range of industries.

He has acted for investors and venture capital funds as well as participated in nearly 100 separate capital raisings, from seed equity to complex syndicated debt and hybrid raisings in international markets.

His various roles have provided extensive experience in strategic planning, corporate finance, negotiating and structuring transactions, liaising with regulatory authorities and regulatory compliance in jurisdictions around the world.

He regularly contributes time to the earliest stage ventures, incubators and other groups supporting the 'innovation ecosystem' as well as other notable NFP appointments and organisations.

Current Directorships	None
------------------------------	------

Former Directorships	No directorships of ASX listed entities in last 3 years
-----------------------------	---

Relevant interest in Invox Shares	Nil
--	-----

4.3 Board Recommendation

The Directors (other than Mr Owen) unanimously recommend that Shareholders vote in favour of Resolution 3.

4.4 Chairman's available proxies

The Chairman intends to vote all available proxies in favour of this Resolution.

5. RESOLUTION 4 – ELECTION OF DIRECTOR – PROF WARREN HARDING AM

5.1 Background

The Company announced on 10 November 2025 that Prof Warren Harding AM had been appointed as a non-executive Director effective immediately. Prof Harding offers himself up for election at this Meeting.

Resolution 4 is an ordinary resolution for the election of Prof Harding as a Director. If the Resolution is not passed, Prof Harding will not be elected as a Director.

5.2 Listing Rule and Constitutional Requirements

Under Listing Rule 14.4, a Director appointed to fill a casual vacancy or as an addition to the Board must not hold office, without re-election, past the next annual general meeting of the Company.

Clause 15.4 of the Constitution enables the Directors to appoint any person as a Director (either as a casual vacancy or an addition), provided that the relevant appointed director shall only hold office until the next annual general meeting and is eligible for re-election at that meeting.

As the Meeting is the Company's first annual general meeting since Prof Harding's appointment, in accordance with Listing Rule 14.4 and clause 15.4 of the Constitution, Prof Harding resigns as a Director at the Meeting and, being eligible, seeks approval to be elected as a Director pursuant to this Resolution.

Prof Warren Harding AM

Position	Non-Executive Director
-----------------	------------------------

Biography	Professor Warren Harding AM is an experienced company director with more than 30 years of leadership experience across global healthcare, biotech and medtech industries. He was Managing Partner in global strategy/ consulting companies Accenture, Deloitte and PWC including Senior Adviser to McKinsey & Co and has extensive experience in corporate governance, strategic transformation and growth. He has been involved in various mergers/acquisitions at a global and national level.
------------------	--

He is Chair of Alzheimer's WA, a NFP addressing the progressive neurological decline of dementia. He is a member of the Finance Audit and Risk Committee and Chairs the Research and Partnership Committee. He was a Government appointed member of the WA Disability Services Commission 2020-24 and is currently a Federal Cabinet appointed Board director of the Australian Digital Health Agency.

He is co-founder and director of two emerging medtech companies involved in real time patient data telemetry and AI enabled alerts; and early digital detection of dementia to enable more timely use of monoclonal antibodies.

Professor Harding holds a Professorship at the School of Medicine, Macquarie University; Bachelor of Science 1st Class Hons, British Council Scholar London School of Economics. He was appointed a Member of the Order of Australia in 2023 for his service to business, technology and community health.

Current Directorships	None
------------------------------	------

Former Directorships	No directorships of ASX listed entities in last 3 years
-----------------------------	---

Relevant interest in Invex Shares	Nil
--	-----

5.3 Board Recommendation

The Directors (other than Prof Harding) unanimously recommend that Shareholders vote in favour of Resolution 4.

5.4 Chairman's available proxies

The Chairman intends to vote all available proxies in favour of this Resolution.

6. RESOLUTION 5 – APPROVAL OF 7.1A MANDATE

6.1 Background

Listing Rule 7.1A enables eligible entities to issue Equity Securities of up to 10% of its issued ordinary share capital through placements over a 12 month period following the entity's annual general meeting (or, if earlier than 12 months, until the entity's next annual general meeting, or the time and date of an approval of the entity's shareholders of a transaction under Listing Rule 11.1.2 or 11.2) (**7.1A Mandate**). The 7.1A Mandate is in addition to the Company's 15% placement capacity under Listing Rule 7.1.

An eligible entity for the purposes of Listing Rule 7.1A is an entity that is not included in the S&P/ASX 300 Index and has a market capitalisation of \$300 million or less, as at the time of the entity's annual general meeting. The Company is an eligible entity as at the time of this Notice and is expected to be an eligible entity as at the time of the Meeting.

The Company is seeking a mandate to issue securities under the 7.1A Mandate as it will give the Company the flexibility to raise additional working capital whilst preserving the Company's cash reserves.

Equity Securities issued under the 7.1A Mandate must be the same as an existing class of Equity Securities of the Company quoted on ASX.

As at the date of this Notice, the Company has only one class of quoted Equity Securities on issue, being fully paid ordinary Shares.

The exact number of Equity Securities that the Company may issue under the 7.1A Mandate will be determined in accordance with the formula prescribed in Listing Rule 7.1A.2 (refer to section 6.4 of this Notice below).

For this Resolution to be passed, at least 75% of votes cast by Shareholders present and eligible to vote at the Meeting must be cast in favour of the Resolution.

6.2 Listing Rule Requirements

Broadly speaking, and subject to a number of exceptions, Listing Rule 7.1 limits the amount of equity securities that a listed company can issue without the approval of its shareholders over any 12 month period to 15% of the fully paid ordinary shares it had on issue at the start of that period.

Under Listing Rule 7.1A, however, an eligible entity can seek approval from its members, by way of a special resolution passed at its annual general meeting, to increase this 15% limit by an extra 10% to 25%.

An 'eligible entity' means an entity which is not included in the S&P/ASX 300 Index and which has a market capitalisation of \$300 million or less. The Company is an eligible entity for these purposes.

6.3 Technical information required by Listing Rule 14.1A

If this Resolution is passed, the Company will be able to issue Equity Securities up to the combined 25% limit in Listing Rules 7.1 and 7.1A without any further Shareholder approval.

If this Resolution is not passed, the Company will not be able to access the additional 10% capacity to issue Equity Securities without Shareholder approval under Listing Rule 7.1A and will remain subject to the 15% limit on issuing Equity Securities without Shareholder approval set out in Listing Rule 7.1.

6.4

Technical information required by Listing Rule 7.3A

REQUIRED INFORMATION	DETAILS
<p>Period for which the 7.1A Mandate is valid</p>	<p>The 7.1A Mandate will commence on the date of the Meeting and expire on the first to occur of the following:</p> <ul style="list-style-type: none"> (a) the date that is 12 months after the date of this Meeting; (b) the time and date of the Company's next annual general meeting; and (c) the time and date of approval by Shareholders of any transaction under Listing Rule 11.1.2 (a significant change in the nature or scale of activities) or Listing Rule 11.2 (disposal of the main undertaking).
<p>Minimum price</p>	<p>Any Equity Securities issued under the 7.1A Mandate must be in an existing quoted class of Equity Securities and be issued for cash consideration at a minimum price of 75% of the volume weighted average price of Equity Securities in that class, calculated over the 15 trading days on which trades in that class were recorded immediately before:</p> <ul style="list-style-type: none"> (a) the date on which the price at which the Equity Securities are to be issued is agreed by the entity and the recipient of the Equity Securities; or (b) if the Equity Securities are not issued within 10 trading days of the date in paragraph (a) above, the date on which the Equity Securities are issued.
<p>Use of funds</p>	<p>The Company intends to use funds raised from issues of Equity Securities under the 7.1A Mandate for additional research and development projects, potential acquisitions, meet financial commitments as well as for general working capital.</p>
<p>Risk of economic and voting dilution</p>	<p>The precise number of Equity Securities that the Company will have capacity to issue under Listing Rule 7.1A will be calculated at the date of issue of the Equity Securities in accordance with the following formula:</p> $\text{Additional Placement Capacity} = (A \times D) - E$ <p>where:</p> <p>A is the number of Shares on issue 12 months before the date of issue or agreement:</p> <ul style="list-style-type: none"> • plus the number of Shares issued in the 12-month period immediately preceding the date of the issue or agreement (Relevant Period) under an exception in Listing Rule 7.2 (other than exceptions 9, 16 or 17); • plus the number of Shares issued in the Relevant Period on the conversion of convertible securities within Listing Rule 7.2 exception 9 where: <ul style="list-style-type: none"> ○ the convertible securities were issued or agreed to be issued before the commencement of the Relevant Period; or ○ the issue of, or agreement to issue, the convertible securities was approved, or taken under these rules to have been approved, under Listing Rule 7.1 or 7.4; • plus the number of Shares issued in the Relevant Period under an agreement to issue securities within Listing Rule 7.2 exception 16 where: <ul style="list-style-type: none"> ○ the agreement was entered into before the commencement of the Relevant Period; or

REQUIRED INFORMATION	DETAILS																																								
	<ul style="list-style-type: none"> ○ the agreement or issue was approved, or taken under these rules to have been approved, under Listing Rule 7.1 or 7.4; • plus the number of Shares issued in the Relevant Period with approval under Listing Rules 7.1 or 7.4; • plus the number of partly paid ordinary securities that became fully paid in the Relevant Period; and • less the number of Shares cancelled in the Relevant Period; <p>D is 10%; and</p> <p>E is the number of equity securities issued or agreed to be issued under Listing Rule 7.1A.2 in the Relevant Period where the issue or agreement has not been subsequently approved by the Shareholders under Listing Rule 7.4.</p> <p>Any issue of Equity Securities under the 7.1A Mandate will dilute the interests of Shareholders who do not receive any Shares under the issue.</p> <p>If this Resolution is approved by Shareholders and the Company issues the maximum number of Equity Securities available under the 7.1A Mandate, the economic and voting dilution of existing Shares would be as shown in the table below.</p> <p>The table below shows the dilution of existing Shareholders calculated in accordance with the formula outlined in Listing Rule 7.1A.2, on the basis of the closing market price of Shares and the number of Equity Securities on issue proposed to be issued as at 9 January 2026.</p> <p>The table also shows the voting dilution impact where the number of Shares on issue (Variable A in the formula) changes and the economic dilution where there are changes in the issue price of Shares issued under the 7.1A Mandate.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="3" style="text-align: center;">Number of Shares on Issue (Variable A in Listing Rule 7.1A.2)</th> <th rowspan="3"></th> <th rowspan="3" style="text-align: center;">Shares issued – 10% voting dilution</th> <th colspan="3" style="text-align: center;">Issue Price</th> </tr> <tr> <th style="text-align: center;">\$0.055</th> <th style="text-align: center;">\$0.11</th> <th style="text-align: center;">\$0.165</th> </tr> <tr> <th style="text-align: center;">50% decrease</th> <th style="text-align: center;">Issue Price</th> <th style="text-align: center;">50% increase</th> </tr> <tr> <th colspan="6" style="text-align: center;">Funds Raised</th> </tr> </thead> <tbody> <tr> <td style="text-align: center;">Current</td> <td style="text-align: right;">75,153,848</td> <td style="text-align: right;">7,515,384</td> <td style="text-align: right;">\$413,344</td> <td style="text-align: right;">\$826,687</td> <td style="text-align: right;">\$1,240,031</td> </tr> <tr> <td style="text-align: center;">50% increase</td> <td style="text-align: right;">112,730,772</td> <td style="text-align: right;">11,273,077</td> <td style="text-align: right;">\$620,015</td> <td style="text-align: right;">\$1,240,031</td> <td style="text-align: right;">\$1,860,046</td> </tr> <tr> <td style="text-align: center;">100% increase</td> <td style="text-align: right;">150,306,768</td> <td style="text-align: right;">15,030,676</td> <td style="text-align: right;">\$826,687</td> <td style="text-align: right;">\$1,653,374</td> <td style="text-align: right;">\$2,480,062</td> </tr> </tbody> </table> <p>*The number of Shares on issue (Variable A in the formula) could increase as a result of the issue of Shares that do not require Shareholder approval (such as under a pro-rata rights issue or scrip issued under a takeover offer) or that are issued with Shareholder approval under Listing Rule 7.1.</p> <p>The table above uses the following assumptions:</p> <ol style="list-style-type: none"> 1. There are currently 75,153,848 Shares on issue. 2. The issue price set out above is the closing market price of the Shares on the ASX on 9 January 2026 (being \$0.11). 					Number of Shares on Issue (Variable A in Listing Rule 7.1A.2)		Shares issued – 10% voting dilution	Issue Price			\$0.055	\$0.11	\$0.165	50% decrease	Issue Price	50% increase	Funds Raised						Current	75,153,848	7,515,384	\$413,344	\$826,687	\$1,240,031	50% increase	112,730,772	11,273,077	\$620,015	\$1,240,031	\$1,860,046	100% increase	150,306,768	15,030,676	\$826,687	\$1,653,374	\$2,480,062
Number of Shares on Issue (Variable A in Listing Rule 7.1A.2)		Shares issued – 10% voting dilution	Issue Price																																						
			\$0.055	\$0.11	\$0.165																																				
			50% decrease	Issue Price	50% increase																																				
Funds Raised																																									
Current	75,153,848	7,515,384	\$413,344	\$826,687	\$1,240,031																																				
50% increase	112,730,772	11,273,077	\$620,015	\$1,240,031	\$1,860,046																																				
100% increase	150,306,768	15,030,676	\$826,687	\$1,653,374	\$2,480,062																																				

REQUIRED INFORMATION	DETAILS
	<p>3. The Company issues the maximum possible number of Equity Securities under the 7.1A Mandate.</p> <p>4. The Company has not issued any Equity Securities in the 12 months prior to the Meeting that were not issued under an exception in Listing Rule 7.2 or with approval under Listing Rule 7.1/7.1A.</p> <p>5. The issue of Equity Securities under the 7.1A Mandate consists only of Shares. It is assumed that no Options are exercised into Shares before the date of issue of the Equity Securities. If the issue of Equity Securities includes quoted Options, it is assumed that those quoted Options are exercised into Shares for the purpose of calculating the voting dilution effect on existing Shareholders.</p> <p>6. The calculations above do not show the dilution that any one particular Shareholder will be subject to. All Shareholders should consider the dilution caused to their own shareholding depending on their specific circumstances.</p> <p>7. This table does not set out any dilution pursuant to approvals under Listing Rule 7.1 unless otherwise disclosed.</p> <p>8. The 10% voting dilution reflects the aggregate percentage dilution against the issued share capital at the time of issue. This is why the voting dilution is shown in each example as 10%.</p> <p>9. The table does not show an example of dilution that may be caused to a particular Shareholder by reason of placements under the 7.1A Mandate, based on that Shareholder's holding at the date of the Meeting.</p> <p>Shareholders should note that there is a risk that:</p> <p>(a) the market price for the Company's Shares may be significantly lower on the issue date than on the date of the Meeting; and</p> <p>(b) the Shares may be issued at a price that is at a discount to the market price for those Shares on the date of issue.</p>
<p>Allocation policy under 7.1A Mandate</p>	<p>The recipients of the Equity Securities to be issued under the 7.1A Mandate have not yet been determined. However, the recipients of Equity Securities could consist of current Shareholders or new investors (or both), none of whom will be related parties of the Company.</p> <p>The Company will determine the recipients at the time of the issue under the 7.1A Mandate, having regard to the following factors:</p> <p>(a) the purpose of the issue;</p> <p>(b) alternative methods for raising funds available to the Company at that time, including, but not limited to, an entitlement issue, share purchase plan, placement or other offer where existing Shareholders may participate;</p> <p>(c) the effect of the issue of the Equity Securities on the control of the Company;</p> <p>(d) the circumstances of the Company, including, but not limited to, the financial position and solvency of the Company;</p> <p>(e) prevailing market conditions; and</p> <p>(f) advice from corporate, financial and broking advisers (if applicable).</p>
<p>Previous approval under Listing Rule 7.1A.2</p>	<p>The Company previously obtained approval from its Shareholders pursuant to Listing Rule 7.1A at its annual general meeting held on 26 November 2024 (Previous Approval).</p>

REQUIRED INFORMATION	DETAILS
	During the 12-month period preceding the date of the Meeting, the Company has not issued any Equity Securities pursuant to the Previous Approval.
Voting exclusion statement	As at the date of this Notice, the Company is not proposing to make an issue of Equity Securities under Listing Rule 7.1A. Accordingly, a voting exclusion statement is not included in this Notice.

6.5 Board Recommendation

The Directors unanimously recommend that Shareholders vote in favour of this resolution as it will give the Company the flexibility to raise additional working capital whilst preserving the Company's cash reserves.

For personal use only

GLOSSARY

\$ means Australian dollars.

ASIC means the Australian Securities & Investments Commission.

ASX means ASX Limited (ACN 008 624 691) or the financial market operated by ASX Limited, as the context requires.

Board means the current board of directors of the Company.

Chairman means the chair of the Meeting.

Closely Related Party of a member of the Key Management Personnel means:

- (a) a spouse or child of the member;
- (b) a child of the member's spouse;
- (c) a dependent of the member or the member's spouse;
- (d) anyone else who is one of the member's family and may be expected to influence the member, or be influenced by the member, in the member's dealing with the entity;
- (e) a company the member controls; or
- (f) a person prescribed by the Corporations Regulations 2001 (Cth) for the purposes of the definition of 'closely related party' in the Corporations Act.

Company means Invex Therapeutics Ltd (ACN 632 145 334).

Constitution means the Company's constitution.

Corporations Act means the *Corporations Act 2001* (Cth).

Directors means the current directors of the Company.

Equity Security Has the meaning given to that term in Listing Rule 19.12, being:

- (a) a share;
- (b) a unit;
- (c) a right to a share or unit or option;
- (d) an option over an issued or unissued security;
- (e) a convertible security;
- (f) any security that ASX decides to classify as an equity security;
- (g) but not a security that ASX decides to classify as a debt security.

Explanatory Memorandum means the explanatory memorandum accompanying the Notice.

Key Management Personnel has the same meaning as in the accounting standards issued by the Australian Accounting Standards Board and means those persons having authority and responsibility for planning, directing and controlling the activities of the Company, or if the Company is part of a consolidated entity, of the consolidated entity, directly or indirectly, including any director (whether executive or otherwise) of the Company, or if the Company is part of a consolidated entity, of an entity within the consolidated group.

Meeting means the meeting convened by the Notice.

Notice means this notice of meeting including the Explanatory Memorandum and the Proxy Form.

Proxy Form means the proxy form accompanying the Notice.

Remuneration Report means the remuneration report set out in the Director's report section of the Company's annual financial report for the year ended 30 June 2025.

Resolutions means the resolutions set out in the Notice, or any one of them, as the context requires.

Share means a fully paid ordinary share in the capital of the Company.

Shareholder means a registered holder of a Share.

WST means Western Standard Time as observed in Perth, Western Australia.

Proxy Voting Form

If you are attending the Meeting in person, please bring this with you for Securityholder registration.

Your proxy voting instruction must be received by **3:00pm (AWST) on Sunday, 15 February 2026**, being **not later than 48 hours** before the commencement of the Meeting. Any Proxy Voting instructions received after that time will not be valid for the scheduled Meeting.

SUBMIT YOUR PROXY

Complete the form overleaf in accordance with the instructions set out below.

YOUR NAME AND ADDRESS

The name and address shown above is as it appears on the Company's share register. If this information is incorrect, and you have an Issuer Sponsored holding, you can update your address through the investor portal: <https://investor.automic.com.au/#/home> Shareholders sponsored by a broker should advise their broker of any changes.

STEP 1 - APPOINT A PROXY

If you wish to appoint someone other than the Chair of the Meeting as your proxy, please write the name of that Individual or body corporate. A proxy need not be a Shareholder of the Company. Otherwise if you leave this box blank, the Chair of the Meeting will be appointed as your proxy by default.

DEFAULT TO THE CHAIR OF THE MEETING

Any directed proxies that are not voted on a poll at the Meeting will default to the Chair of the Meeting, who is required to vote these proxies as directed. Any undirected proxies that default to the Chair of the Meeting will be voted according to the instructions set out in this Proxy Voting Form, including where the Resolutions are connected directly or indirectly with the remuneration of Key Management Personnel.

STEP 2 - VOTES ON ITEMS OF BUSINESS

You may direct your proxy how to vote by marking one of the boxes opposite each item of business. All your shares will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of shares you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on the items of business, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

APPOINTMENT OF SECOND PROXY

You may appoint up to two proxies. If you appoint two proxies, you should complete two separate Proxy Voting Forms and specify the percentage or number each proxy may exercise. If you do not specify a percentage or number, each proxy may exercise half the votes. You must return both Proxy Voting Forms together. If you require an additional Proxy Voting Form, contact Automic Registry Services.

SIGNING INSTRUCTIONS

Individual: Where the holding is in one name, the Shareholder must sign.

Joint holding: Where the holding is in more than one name, all Shareholders should sign.

Power of attorney: If you have not already lodged the power of attorney with the registry, please attach a certified photocopy of the power of attorney to this Proxy Voting Form when you return it.

Companies: To be signed in accordance with your Constitution. Please sign in the appropriate box which indicates the office held by you.

Email Address: Please provide your email address in the space provided.

By providing your email address, you elect to receive all communications despatched by the Company electronically (where legally permissible) such as a Notice of Meeting, Proxy Voting Form and Annual Report via email.

CORPORATE REPRESENTATIVES

If a representative of the corporation is to attend the Meeting the appropriate 'Appointment of Corporate Representative' should be produced prior to admission. A form may be obtained from the Company's share registry online at <https://automicgroup.com.au>.

Lodging your Proxy Voting Form:

Online

Use your computer or smartphone to appoint a proxy at <https://investor.automic.com.au/#/loginsah> or scan the QR code below using your smartphone

Login & Click on 'Meetings'. Use the Holder Number as shown at the top of this Proxy Voting Form.



BY MAIL:

Automic
GPO Box 5193
Sydney NSW 2001

IN PERSON:

Automic
Level 5, 126 Phillip Street
Sydney NSW 2000

BY EMAIL:

meetings@automicgroup.com.au

BY FACSIMILE:

+61 2 8583 3040

All enquiries to Automic:

WEBSITE:

<https://automicgroup.com.au>

PHONE:

1300 288 664 (Within Australia)
+61 2 9698 5414 (Overseas)

